Manvitha Reddy Has Died in Baltimore
The 26-year-old woman passed away after a 57-day battle with Stage 4 Squamous Cell Carcinoma.
Updated on Oct. 2, 2026 in Cancer

Manvitha Reddy, a 26-year-old from Telangana, India, has died following a brief struggle with Stage 4 Squamous Cell Carcinoma. She passed away in Baltimore, Maryland, after receiving medical care in the city.
Why it matters
The untimely death of a young international student or resident has prompted a community effort to facilitate the repatriation of her remains. Her passing highlights the rapid progression of aggressive cancers.
Manvitha Reddy was 26 years old at the time of her death. Her battle with the illness spanned 57 days from the onset of intensive medical intervention.
The players
Manvitha Reddy
She was a 26-year-old individual from Telangana, India, who was receiving medical care in Baltimore.
The details
Reddy received intensive treatment at a local hospital in Baltimore during the final weeks of her life. While she was away from her home in India, she was supported throughout her illness by cousins and friends living in the United States.
Timeline
October 2026: Manvitha Reddy passed away in Baltimore.
The Big Picture
This case follows the clinical pattern of aggressive Stage 4 Squamous Cell Carcinoma monitored by the National Cancer Institute's Head and Neck Cancer research initiatives. It highlights the rapid mortality rates that can occur even with intensive medical care.
This case serves as a reminder of the importance of early screening for persistent symptoms that may indicate squamous cell growths. Residents experiencing unexplained health changes should consult their primary care providers for early diagnostic testing.
The takeaway
Early detection remains the most effective tool in managing aggressive malignancies before they reach advanced stages. If you or a loved one notice unusual health symptoms, seeking immediate medical evaluation is critical for potential intervention.
Further reading
Learn more about the latest oncological developments in the Cancer section.










